Biological Activity:

ZLN005 is a potent and selective small molecule PGC-1α transcriptional activator. It stimulates the expression of PGC-1α and downstream genes in skeletal muscle cells, improving glucose utilization and fatty acid oxidation. Chronic oral administration of ZLN005 at 15 mg/kg per day to diabetic db/db mice increased PGC-1α and downstream gene transcription in skeletal muscle, increasing fat oxidation and improving glucose tolerance, pyruvate tolerance, and insulin sensitivity. PGC-1α is a tissue-specific and inducible transcriptional coactivator for several nuclear receptors and plays a key role in energy metabolism, hepatic gluconeogenesis, and cholesterol homoeostasis. ZLN005 is a useful chemical probe to study this target.

How to Use:

• In vitro:  ZLN005 was used at 10-20 µM final concentration in various in vitro assays.
• In vivo: ZLN005 was orally administrated in db/db mice at 15 mg/kg once per day for 6 weeks.

Reference: 

1. 1. Zhang LN, et al. Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. (2013) Diabetes. 62(4):1297-307.

Products are for research use only. Not for human use.